<DOC>
	<DOCNO>NCT01832948</DOCNO>
	<brief_summary>This study ass efficacy safety Endostar combine mFOLFOX6 untreated metastatic colorectal cancer patient , find marker may predict efficacy .</brief_summary>
	<brief_title>Endostar Combined With mFOLFOX6 First-line Treatment Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Histologically cytologically confirm metastatic colorectal cancer ( adenocarcinoma ) At least one measurable lesion ( RECIST criterion ) Life expectancy ≥ 3 month ECOG performance status 02 Adequate hematologic function : ANC ≥ 1.5×109 /L，Hb ≥ 90 g/L，PLT ≥ 100×109 /L Adequate renal function : Cr ≤ 1.25×ULN Creatinine clearance ≥ 60 ml/min Adequate hepatic function : BIL ≤ 1.5×ULN , ALT/AST ≤ 2.5×ULN , Alkaline phosphatase ≤ 5×ULN Patients previously receive palliative chemotherapy , immunological/ biological treatment No adjuvant chemotherapy last six month Target lesion receive local radiotherapy Written inform consent Diagnosis colorectal neuroendocrine tumor , undifferentiated carcinoma , adenosquamous carcinoma , squamous cell carcinoma Evidence serious uncontrolled infection Serious cardiovascular disease ( congestive heart failure , uncontrollable arrhythmia , unstable angina , myocardial infarction , serious heart valve disease , resistant hypertension ) Pregnant lactate woman Women childbearing potential refused practice acceptable method birth control prevent pregnancy Allergic study drug Intestinal obstruction , intestinal perforation , stroke within 3 month Participation clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>